Humanized Anti-TROP2 Antibodies for Higher Affinity Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drugs targeting TROP2 for cancer therapy, such as IMMU-132, face challenges in efficacy and specificity, particularly in treating cancers like triple-negative breast cancer, and there is a need for improved therapeutic antibodies that can effectively target and inhibit TROP2 overexpression in various tumors.
Innovation Solution
Development of chimeric and humanized monoclonal antibodies with specific complementarity-determining regions (CDRs) that bind to human TROP2 protein, optimized through immunization and genetic recombination, enhancing their therapeutic potential by improving affinity and biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If murine monoclonal antibodies are used to target TROP2, then binding capability is achieved, but immunogenicity increases and therapeutic efficacy is limited
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's species origin from murine to humanized or chimeric variants. This changes the immunogenicity parameter while maintaining TROP2 binding capability, thereby improving therapeutic efficacy in human patients by reducing immune system rejection of the therapeutic antibody.
Solution Approach 2:
The patent uses chimeric and humanized antibody structures as intermediaries between fully murine antibodies and fully human antibodies. These intermediate forms retain the proven binding specificity of murine antibodies against TROP2 while reducing immunogenicity through human sequence incorporation, serving as a transitional solution to improve therapeutic reliability.
2Reliability
If antibody structure is optimized for higher affinity, then binding capability improves, but development complexity increases
Solution Approach 1:
The patent applies local quality by making specific modifications to the CDR (complementarity-determining region) sequences of the antibody while keeping the overall antibody framework structure intact. This localized optimization of binding regions improves affinity for TROP2 without requiring complete redesign of the entire antibody molecule, thereby managing development complexity.
Solution Approach 2:
The patent employs dynamic optimization strategies where antibody sequences are iteratively refined through immunization and selection processes. The CDR regions are dynamically adjusted to enhance binding affinity to TROP2, allowing the antibody to evolve toward higher effectiveness while maintaining a systematic development approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The developed antibodies demonstrate enhanced binding and endocytosis capabilities, offering improved therapeutic potential for targeting TROP2-expressing cancers, with humanized versions showing increased stability and affinity, thereby potentially increasing treatment efficacy.
Implementation Method 1
anti-TROP2 antibody... that can specifically bind to human TROP2 protein
Implementation Method 2
The developed antibodies demonstrate enhanced binding and endocytosis capabilities
Data Source
AI summary
The present disclosure relates to antibodies, in particular monoclonal antibodies of murine, chimeric, and humanized origin, that specifically bind to the human TROP2 protein, and to the amino acid and nucleotide sequences encoding these antibodies. The disclosure also discloses the use of these antibodies as a diagnostic reagent or a drug in the diagnostic and/or therapeutic management of malignancies or any lesion related to the overexpression of the receptor.